Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies.

Biotechnology

Pharmaceutical

Therapeutics

Immune-Onc Therapeutics

Charlene Liao

Helen Y.

Ying Zhu

Xiao Min Schebye

Wen Hong Lin

Sydney Ray

Roya Nawabi

Penny Dong

Kyu Hee Hong

Donna Valencia

tao Huang

Hong Xiang

Christopher Whitmore

Maggie Gu

The Scientific and Clinical Team at Immune-Onc Therapeutics is responsible for spearheading the discovery and development of novel myeloid checkpoint inhibitors. This team merges extensive scientific research with clinical expertise to advance innovative cancer immunotherapies through rigorous preclinical and clinical trials, ensuring both efficacy and safety in treating cancer patients.

Scientific and Clinical Team

Directors Team

Leadership Team

Scientific and Clinical Team

About

Team members

Other teams at Immune-Onc Therapeutics

Directors Team

Leadership Team